On July 22, 2026, Astrana Health Inc ASTH shares fell 7.7% today, bringing the current price to $41.91. The stock has experienced a 52-week range of $18.08 to $51.60, highlighting significant volatility in its recent performance.
- GF Valueâ„¢ verdict: The stock is currently priced at $41.91, which is 49.7% below the GF Valueâ„¢ estimate of $83.40.
- GF Scoreâ„¢ of 85/100 indicates a strong overall ranking based on multiple performance metrics.
- Notable signal: There have been no insider transactions in the last 3 months.
Is ASTH Overvalued or Undervalued?
Astrana Health Inc ASTH is currently trading at $41.91, which represents a significant discount compared to its GF Value™ estimate of $83.40. This valuation suggests that the stock is undervalued by approximately 49.7%, presenting a potential opportunity for investors. The GF Valuation label indicates that the stock is significantly undervalued, which could imply that the market has not fully recognized the company’s growth potential or its future earnings capabilities.
GF Valueâ„¢ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. This methodology provides a comprehensive view of a company's value, considering various financial metrics and growth prospects. However, while the undervaluation presents an opportunity, investors should remain cautious due to the inherent risks involved, especially given the stock's recent performance trends.
How Does ASTH's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 68.8x | 35.1x |
| Forward P/E | 33.0x | N/A |
The current P/E ratio of 68.8x is significantly above its 5-year median P/E of 35.1x, indicating that the stock is trading at a higher valuation compared to its historical averages. This discrepancy aligns with the GF Valueâ„¢ verdict, suggesting that while the stock appears undervalued in terms of GF Valueâ„¢, the high P/E ratio indicates a premium valuation that could reflect market skepticism about achieving expected growth.
What Does ASTH's GF Scoreâ„¢ Tell Us?
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 85 |
| Financial Strength | 6/10 |
| Profitability | 7/10 |
| Growth | 10/10 |
| Valuation | 4/10 |
| Momentum | 6/10 |
The GF Scoreâ„¢ of 85/100 indicates a strong overall performance for Astrana Health Inc, driven primarily by its exceptional growth rank of 10/10. This reflects the company's robust potential for future earnings growth. However, the valuation rank of 4/10 suggests that the current price may not fully justify the company's growth prospects, indicating a strong divergence between market expectations and intrinsic value. Financial strength and profitability ranks are moderate, further emphasizing the need for cautious evaluation of the stock.
What Are Insiders Doing with ASTH Stock?
In recent months, there have been no insider transactions reported for Astrana Health Inc. This lack of activity may suggest a level of uncertainty or confidence among insiders regarding the company's future performance. The absence of buying or selling could indicate that insiders are not currently taking advantage of the stock's price fluctuations, which may be a point of concern for potential investors.
What This Means for Investors
Based on the GF Valueâ„¢ assessment, Astrana Health Inc ASTH appears to be undervalued, offering a significant margin of safety at its current price of $41.91 compared to the GF Valueâ„¢ estimate of $83.40. However, investors should consider the high P/E ratio and the recent stock performance, which may warrant a cautious approach.
For the complete analysis, visit the Astrana Health Inc ASTH stock page. You can also explore the GF Valueâ„¢ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is ASTH's GF Scoreâ„¢?
ASTH's GF Scoreâ„¢ is 85/100, indicating a strong overall performance based on key financial metrics.
Is ASTH overvalued or undervalued?
ASTH is currently undervalued, with a GF Valueâ„¢ estimate of $83.40 compared to its current price of $41.91.
What is ASTH's P/E ratio?
ASTH's P/E (TTM) is 68.8x, which is significantly above its 5-year median P/E of 35.1x, suggesting a premium valuation that may not align with its historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
